Your browser doesn't support javascript.
loading
Development of a Multivariate Prediction Model for Early-Onset Bronchiolitis Obliterans Syndrome and Restrictive Allograft Syndrome in Lung Transplantation.
Koutsokera, Angela; Royer, Pierre J; Antonietti, Jean P; Fritz, Andreas; Benden, Christian; Aubert, John D; Tissot, Adrien; Botturi, Karine; Roux, Antoine; Reynaud-Gaubert, Martine L; Kessler, Romain; Dromer, Claire; Mussot, Sacha; Mal, Hervé; Mornex, Jean-François; Guillemain, Romain; Knoop, Christiane; Dahan, Marcel; Soccal, Paola M; Claustre, Johanna; Sage, Edouard; Gomez, Carine; Magnan, Antoine; Pison, Christophe; Nicod, Laurent P.
Afiliação
  • Koutsokera A; Division of Pulmonary Medicine, Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Lausanne, Switzerland.
  • Royer PJ; Institut du thorax, INSERM UMR 1087/CNRS UMR 6291, CHU de Nantes, Université de Nantes, Nantes, France.
  • Antonietti JP; Division of Pulmonary Medicine, Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Lausanne, Switzerland.
  • Fritz A; Biomax Informatics AG, Planegg, Germany.
  • Benden C; Division of Pulmonary Medicine, University Hospital Zurich, Zurich, Switzerland.
  • Aubert JD; Division of Pulmonary Medicine, Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Lausanne, Switzerland.
  • Tissot A; Institut du thorax, INSERM UMR 1087/CNRS UMR 6291, CHU de Nantes, Université de Nantes, Nantes, France.
  • Botturi K; Institut du thorax, INSERM UMR 1087/CNRS UMR 6291, CHU de Nantes, Université de Nantes, Nantes, France.
  • Roux A; Pneumology, Adult CF Center and Lung transplantation Department, Foch Hospital, Université Versailles Saint-Quentin-en-Yvelines, UPRES EA220, Suresnes, France.
  • Reynaud-Gaubert ML; Pulmonary Medicine, CF Center and Lung Transplantation Department, Centre Hospitalier Universitaire Nord, CNRS UMR 6236 Aix-Marseille Université, Marseille, France.
  • Kessler R; Lung Transplant Center, Hôpitaux universitaires de Strasbourg, Strasbourg, France.
  • Dromer C; Service des Maladies respiratoires, Hôpital Haut Lévèque, Pessac, France.
  • Mussot S; Service de Chirurgie Thoracique, Vasculaire et Transplantation Cardiopulmonaire, Hôpital Marie Lannelongue, Le Plessis Robinson, France.
  • Mal H; Service de Pneumologie et Transplantation pulmonaire, Hôpital Bichat, Université Denis Diderot, INSERM UMR1152, Paris, France.
  • Mornex JF; Université de Lyon, INRA UMR 754, Hospices civils de Lyon, Lyon, France.
  • Guillemain R; Assistance Publique Hôpitaux de Paris, Paris, France.
  • Knoop C; Department of Chest Medicine, Erasme University Hospital, Brussels, Belgium.
  • Dahan M; CHU Larrey, Toulouse, France.
  • Soccal PM; Division of Pulmonary Medicine, Geneva University Hospitals, Geneva, Switzerland.
  • Claustre J; Clinique Universitaire de Pneumologie, Pôle Thorax et Vaisseaux, CHU Grenoble, INSERM 1055, Université Grenoble Alpes, Grenoble, France.
  • Sage E; Thoracic Surgery Department, Foch Hospital, Université Versailles Saint-Quentin-en-Yvelines, UPRES EA220, Suresnes, France.
  • Gomez C; Pulmonary Medicine, CF Center and Lung Transplantation Department, Centre Hospitalier Universitaire Nord, CNRS UMR 6236 Aix-Marseille Université, Marseille, France.
  • Magnan A; Institut du thorax, INSERM UMR 1087/CNRS UMR 6291, CHU de Nantes, Université de Nantes, Nantes, France.
  • Pison C; Clinique Universitaire de Pneumologie, Pôle Thorax et Vaisseaux, CHU Grenoble, INSERM 1055, Université Grenoble Alpes, Grenoble, France.
  • Nicod LP; Division of Pulmonary Medicine, Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Lausanne, Switzerland.
Front Med (Lausanne) ; 4: 109, 2017.
Article em En | MEDLINE | ID: mdl-28770204
BACKGROUND: Chronic lung allograft dysfunction and its main phenotypes, bronchiolitis obliterans syndrome (BOS) and restrictive allograft syndrome (RAS), are major causes of mortality after lung transplantation (LT). RAS and early-onset BOS, developing within 3 years after LT, are associated with particularly inferior clinical outcomes. Prediction models for early-onset BOS and RAS have not been previously described. METHODS: LT recipients of the French and Swiss transplant cohorts were eligible for inclusion in the SysCLAD cohort if they were alive with at least 2 years of follow-up but less than 3 years, or if they died or were retransplanted at any time less than 3 years. These patients were assessed for early-onset BOS, RAS, or stable allograft function by an adjudication committee. Baseline characteristics, data on surgery, immunosuppression, and year-1 follow-up were collected. Prediction models for BOS and RAS were developed using multivariate logistic regression and multivariate multinomial analysis. RESULTS: Among patients fulfilling the eligibility criteria, we identified 149 stable, 51 BOS, and 30 RAS subjects. The best prediction model for early-onset BOS and RAS included the underlying diagnosis, induction treatment, immunosuppression, and year-1 class II donor-specific antibodies (DSAs). Within this model, class II DSAs were associated with BOS and RAS, whereas pre-LT diagnoses of interstitial lung disease and chronic obstructive pulmonary disease were associated with RAS. CONCLUSION: Although these findings need further validation, results indicate that specific baseline and year-1 parameters may serve as predictors of BOS or RAS by 3 years post-LT. Their identification may allow intervention or guide risk stratification, aiming for an individualized patient management approach.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Front Med (Lausanne) Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Suíça

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Front Med (Lausanne) Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Suíça